



## Kenalog®-40 (triamcinolone acetonide) – First-time generic

- On December 12, 2017, [Amneal Biosciences announced](#) the FDA approval of an [AP-rated](#) generic version of Bristol-Myers Squibb's [Kenalog-40 \(triamcinolone acetonide\)](#) injection.
  - Amneal Biosciences' generic Kenalog-40 is poised to launch.
- When oral therapy is not feasible, Kenalog-40 is indicated for intramuscular use for the following conditions: allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmic diseases, renal diseases, respiratory diseases, rheumatic disorders, and some miscellaneous disease states such as trichinosis and tuberculous meningitis under certain conditions.
  - Consult the Kenalog-40 drug label for more detailed indication information.
- Kenalog-40 is also indicated for intra-articular or soft tissue administration as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis.
- Injectable triamcinolone acetonide is also available as the branded product, [Kenalog-10](#).
  - Kenalog-10 carries the same intra-articular or soft tissue administration indications.
  - Consult the Kenalog-10 drug label for additional indications for intralesional administration.
- Annual U.S. sales of Kenalog-40 were \$146 million according to October 2017 IQVIA™ market data.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.